IL33 and neoplasm: Dual therapy with recombinant IL-33 plus anti-PD-1 engaged ILC2s to accumulate in orthotopic KPC tumors and improved T cell infiltration through DC priming, allowing for improved mouse survival and decreased tumor volume (144).